Selected Grants
A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)
Clinical TrialPrincipal Investigator · Awarded by ReGenTree, LLC · 2024 - 2029External Relationships
- Alcon, Inc
- HelpMercy International
- Johnson & Johnson
- Staar Surgical
- himalayan cataract project
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.